Blavatnik Biomedical Accelerator

 

Blavatnik Fellowship in Life Science Entrepreneurship 

 

Entrepreneurs play a crucial role in successful commercialization of new biomedical technologies. The Blavatnik Fellowship in Life Science Entrepreneurship is designed to foster entrepreneurial skills in the life sciences, linking emerging business leaders with breakthrough innovations from across Harvard University. 

This innovative fellowship program provides a select group of Harvard Business School MBA alumni with the opportunity to work with Harvard inventors to promote the commercialization of life science technologies with significant market potential. Harvard's i-lab serves as the hub, providing fellows with space and the opportunity to join an entrepreneurial community. 

Blavatnik Fellows enjoy a unique set of advantages:

  • Mentorship by distinguished business and science leaders of Boston's biopharma and health technology communities    
  • Leadership opportunities, including the opportunity to join and develop founding teams of new ventures    
  • Education and training on a range of topics, including commercial strategy, R&D management, intellectual property, regulatory affairs, business development, and entrepreneurial financing    
  • Financial support in the form of a one-year stipend plus access to funding for due diligence, market research, licensing options and other commercial activities arising from the fellowship 

The Blavatnik Fellowship in Life Science Entrepreneurship is led by Vicki Sato, Ph.D., Professor of Management Practice at Harvard Business School.

Program Details and Application Process 

Admission to the fellowship is competitive and open to HBS MBA alumni who have graduated within the last 7 years. More information can be found in the Program Description below.

Complete Program Description

For further information contact:  blavatnikfellowship@hbs.edu

Please note: This year's application deadline has been extended to April 1, 2016.

To apply:
Blavatnik Fellowship Application 2016


Blavatnik Fellows 

The third group of Blavatnik Fellows is in place for 2015-2016.  Meet the Group

Past Blavatnik Fellows:
Blavatnik Fellows 2014-15
Blavatnik Fellows 2013-14


View this video of achievements and lessons in the inaguaral Blavatnik Fellowship in Life Science Entrepreneurship


Click here for the most recent Blavatnik Fellowship newsletter.

By bringing together expertise and experience from across Harvard, the Accelerator and the HBS Fellows program will further enhance Harvard’s commitment to innovative research and entrepreneurship.

Dean Nitin Nohria

Harvard Business School
 

2015–16 Fellows

Jeffrey Engler (MBA 2011) has a background in product development and medical devices. Most recently, he was cofounder of Podimetrics, a medical device startup that aims to keep diabetic feet healthy. Previously, he cofounded MatchLend, a financial services startup. Before business school, Engler worked for Unitus, a microfinance nonprofit, and Lehman Brothers. He is currently an Entrepreneur in Residence at Rock Health, a digital health seed fund. He has a BA in history from Columbia.

James McLaughlin (MBA 2011) has a background in biotech entrepreneurship and investing. Previously, he worked in life science venture capital at Advanced Technology Ventures (ATV) and Third Rock Ventures (TRV), where he focused on novel rare disease therapeutics. While at TRV, he cofounded Voyager Therapeutics, an adeno-associated virus gene therapy company, where he led operations for the first year after initial venture capital funding had been obtained. Before that, he ran a research and development group focusing on retinal disease and was involved in business development at Ora Inc., a full-service ophthalmic clinical research and product development firm. Most recently, he founded Pathfinder Biologics, an early-stage biotechnology company in Cambridge, Mass. He holds a bachelor’s degree from Colby College.

Jon Puz (MBA 2008) is an entrepreneurial executive with a background in launching, scaling, and advising healthcare technology companies. Since completing his MBA, he has served as a key leader and driven the growth of three successful ventures focusing on digital health, predictive analytics, and the improvement of patient outcomes. His senior-level leadership roles have included strategy, business development, finance, product development, operations, and technology. While pursuing his MBA, Puz collaborated with the Whitesides Research Group and cowrote the business plan for Diagnostics For All, which is the only organization to ever win both the HBS Business Plan Contest (now the New Venture Competition) and the MIT $100K. He also helped launch Diagnostics For All and served as an advisor to the company. Prior to HBS, he served as a strategy and operations consultant in the healthcare practice at Deloitte Consulting. Puz holds a BS in computer science and systems analysis from Miami University (Ohio).

Theresa Tribble (MBA 2009) comes to the Blavatnik Fellowship from SynapDx, an autism diagnostics company, where she served most recently as vice president of commercial strategy. As part of the founding team, she was involved in a number of areas, including marketing, communications, clinical collaborations, business development, product planning, and operations. Tribble started her career at Putnam Associates, which provides strategy consulting services to the pharmaceutical, biotechnology, and medical device industries. She is on the board of the New England chapter of Autism Speaks. She studied English and political science at Wellesley College.

Barry Wohl (MBA 2014) has diverse operating and strategic planning experience in both the medical device and biopharma sectors. He started his career with Medtronic, where he worked as a product design engineer and later as a global clinical trial lead on a variety of vascular and cardiac rhythm implantable devices, many of which went on to capture significant market share. During his time at HBS, Wohl worked on corporate and portfolio strategy at Biogen. Most recently, he worked with global biotech firms of all sizes and development stages as a strategy consultant with IMS Consulting Group and concurrently in a sell-side transaction advisory role with IMS Health Capital. He also cofounded Respira Design, a social enterprise to develop low-cost medical technology for the treatment of respiratory conditions in the developing world, which won the Stanford BASES social enterprise competition. Wohl holds a BS in biomedical engineering, magna cum laude, from Columbia, an MS in mechanical engineering from Stanford.